

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1661R2C1	Serial No. not yet assigned	
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Adams, Camellia et al.		
				Filing Date 08 Jul 2003	Group not yet assigned	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
JB	* 1 5,654,407	05.08.97	Boyle et al.			
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
JB	* 2 WO 91/16353	31.10.91	PCT			
JB	* 3 WO 95/25167	21.09.95	PCT			
JB	* 4 WO 97/26010	24.07.97	PCT			
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>						
JB	* 5	Ahmad and Walsh, "Platelet membrane-mediated coagulation protease complex assembly" <u>Trends in Cardiovascular Medicine</u> 4(6):271-277 (1994)				
	* 6	Ahmad et al., "Coagulation factor IX residues G <sub>4</sub> -Q <sub>11</sub> mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex" <u>Biochemistry</u> 37(6):1671-1679 (Feb 10, 1998)				
	* 7	Ahmad et al., "High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11" <u>Biochemistry</u> 33(40):12048-12055 (Oct 11, 1994)				
	* 8	Bach, R. R., "Initiation of Coagulation by Tissue Factor" <u>CRC Critical Reviews in Biochemistry</u> 23(4):339-368 (1988)				
	* 9	Benedict et al., "Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model" <u>Journal of Clinical Investigation</u> 88(5):1760-1765 (Nov 1991)				
	* 10	Blackburn et al., "Anti-factor IX monoclonal antibody, BC2, is a potent antithrombotic agent" <u>Blood</u> (Abstract #1885) 90(Suppl. 1):424a-425a (1997)				
	* 11	Cheung et al., "Identification of the endothelial cell binding site for factor IX" <u>Proc. Natl. Acad. Sci. USA</u> 93(20):11068-11073 (Oct 1, 1996)				
	* 12	Cheung et al., "The binding of human factor IX to endothelial cells is mediated by residues 3-11" <u>Journal of Biological Chemistry</u> 267(29):20529-20531 (Oct 15, 1992)				
	* 13	Davie et al., "The Coagulation Cascade: Initiation, Maintenance, and Regulation" <u>Biochemistry</u> 30(43):10363-10370 (1991)				
	* 14	Di Scipio et al., "Activation of human factor IX (Christmas factor)" <u>Journal of Clinical Investigation</u> 61(6):1528-1538 (Jun 1978)				
	* 15	Figini et al., "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation" <u>J. Mol. Biol.</u> 239:68-78 (1994)				
	* 16	Fujikawa et al., "The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent)" <u>Biochemistry</u> 13(22):4508-4516 (Oct 22, 1974)				
	* 17	Helmark and Schwartz, "Binding of coagulation factors IX and X to the endothelial cell surface" <u>Biochemical &amp; Biophysical Research Communications</u> 111(2):723-731 (Mar 16, 1983)				
	* 18	Janeway et al. <u>Immunobiology</u> , Garland Press, 4th edition, London NY pps. 87 (1999)				
JB	* 19	Lewis et al <u>Blood</u> 56(4):608-614 (1980)				
Examiner <i>David B. Miller</i>				Date Considered 4/15/05		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1661R2C1	Serial No. not yet assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Adams, Camellia et al.	
				Filing Date 08 Jul 2003	Group not yet assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
28	*20	Lewis et al., "Isolation of CA++-dependent human antibodies to human factor IX" <u>Circulation</u> (abstract #1070) 62(4):III-279 (Oct 1980)			
↓	*21	Liebman et al., "The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa" <u>Journal of Biological Chemistry</u> 262(16):7605-7612 (Jun 5, 1987)			
↓	*22	Liebman, H., "The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX" <u>European Journal of Biochemistry</u> 212(2):339-345 (Mar 1, 1993)			
↓	*23	Limentani et al. <u>Hemostasis and Thrombosis Basic Principles and Clinical Practice</u> , Chapter 5, Coleman et al. Eds., Third edition, Philadelphia: Lippincott Company (1994)			
↓	*24	Mann et al., "Surface-dependent hemostasis" <u>Seminars in Hematology</u> 29(3):213-226 (Jul 1992)			
↓	*25	Osterud and Rapaport, "Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation" <u>Proc. Natl. Acad. Sci. USA</u> 74(12):5260-5264 (Dec 1977)			
↓	*26	Osterud et al., "Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI" <u>Journal of Biological Chemistry</u> 253(17):5946-5951 (Sep 10, 1978)			
↓	*27	Pike et al., "Immunochemical characterization of a monoclonal $\gamma$ G4, A human antibody to factor IX" <u>Blood</u> 40(1):1-10 (Jul 1972)			
↓	*28	Prorok et al., "The entire $\gamma$ -carboxyglutamic acid- and helical stack-domains of human coagulation factor IX are required for optimal binding to its endothelial cell receptor" <u>International Journal of Peptide &amp; Protein Research</u> 48:281-285 (1996)			
↓	*29	Rawala-Sheikh et al., "Role of $\gamma$ -carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation" <u>Blood</u> 79(2):398-405 (Jan 15, 1992)			
↓	*30	Refino et al., "A Human Antibody That Binds to the $\gamma$ -Carboxyglutamic Acid Domain of Factor IX is a Potent Antithrombotic In Vivo." <u>Thrombosis and Haemostasis</u> 82(3):1188-1195 (Sep 1999).			
↓	*31	Reisner et al., "Immunochemical characterization of a polyclonal human antibody to factor IX" <u>Blood</u> 50(1):11-19 (Jul 1977)			
↓	*32	Ryan et al., "Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding" <u>Journal of Biological Chemistry</u> 264(34):20283-20287 (Dec 5, 1989)			
↓	*33	Sekiya et al., "Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions" <u>Journal of Biological Chemistry</u> 270(24):14325-14331 (Jun 16, 1995)			
↓	*34	Spanier et al., "Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog" <u>Journal of Thoracic &amp; Cardiovascular Surgery</u> 115(5):1179-1188 (May 1998)			
↓	*35	Stenflo and Dahlback, "Vitamin K-Dependent Proteins" <u>The Molecular Basis of Blood Diseases</u> , Stamatoyannopoulos et al. eds., 2nd edition, Philadelphia, PA: Saunders pps. 565-598 (1994)			
↓	*36	Suggett et al., "Use of phage display for the generation of human antibodies that neutralize factor IX function" <u>Blood</u> (abstract #2266) 92(10 suppl. 1):551a (Nov 15, 1998)			
↓	*37	Sugo et al., "Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations" <u>Thrombosis Research</u> 58(6):603-614 (Jun 15, 1990)			
↓	*38	Toomey et al., "The endothelial cell binding determinant of human factor IX resides in the $\gamma$ -carboxyglutamic acid domain" <u>Biochemistry</u> 31(6):1806-1808 (Feb. 18, 1992)			
28	*39	Wong et al., "Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis" <u>Thrombosis and Haemostasis</u> 77(6):1143-1147 (Jun 1997)			
Examiner <i>Paul Blumel</i>				Date Considered 4/15/05	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

